NasdaqGS:ALKSBiotechs
Does Sustained Alixorexton Data in Narcolepsy Reshape The Bull Case For Alkermes (ALKS)?
Earlier in July 2026, Alkermes reported interim results from its long-term extension study showing alixorexton produced sustained, clinically meaningful improvements in wakefulness, sleepiness, cognition and fatigue for adults with narcolepsy type 1 and 2, with a generally favorable safety profile across dose groups.
The data, coupled with US and European regulatory designations and ongoing phase 3 Brilliance trials, underscores alixorexton’s potential to anchor Alkermes’ emerging orexin 2...